265 related articles for article (PubMed ID: 33478189)
21. Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.
Abdel-Rahman O; Morris D
Immunotherapy; 2019 Feb; 11(3):149-153. PubMed ID: 30730273
[No Abstract] [Full Text] [Related]
22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
24. Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
Hu W
Thorac Cancer; 2020 Jan; 11(1):3-5. PubMed ID: 31722117
[No Abstract] [Full Text] [Related]
25. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
26. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
28. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy in Epidermal Growth Factor Receptor-mutant
Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):541-545. PubMed ID: 31451147
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
[TBL] [Abstract][Full Text] [Related]
35. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
36. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
37. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Hallqvist A; Rohlin A; Raghavan S
Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859
[TBL] [Abstract][Full Text] [Related]
39. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
40. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
